rss
Br J Ophthalmol 2003;87:1523-1529 doi:10.1136/bjo.87.12.1523
  • Perspective

How much blue light should an IOL transmit?

  1. M A Mainster1,
  2. J R Sparrow2
  1. 1Department of Ophthalmology, University of Kansas Medical School, Kansas City, KS, USA
  2. 2Department of Ophthalmology, Columbia University, New York, NY, USA
  1. Correspondence to: Martin A Mainster PhD, MD, Department of Ophthalmology, MS3009, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160-7379, USA; mmainstekumc.edu
  • Accepted 1 September 2003

Abstract

Older, and even some modern, intraocular lenses (IOLs) transmit potentially hazardous ultraviolet radiation (UVR) to the retina. In addition, IOLs transmit more blue and green light to the retina for scotopic vision than the crystalline lenses they replace, light that is also potentially hazardous. The severity of UVR-blue type phototoxicity increases with decreasing wavelength, unlike the action spectrum of blue-green type retinal phototoxicity and the luminous efficiency of scotopic vision which both peak in the blue-green part of the optical spectrum around 500 nm. Theoretically, UVR+blue absorbing IOLs provide better retinal protection but worse scotopic sensitivity than UVR-only absorbing IOLs, but further study is needed to test this analysis. UVR is potentially hazardous and not useful for vision, so it is prudent to protect the retina from it with chromophores in IOLs. Determining authoritatively how much blue light an optimal IOL should block requires definitive studies to determine (1) the action spectrum of the retinal phototoxicity potentially involved in human retinal ageing, and (2) the amount of shorter wavelength blue light required for older adults to perform essential activities in dimly lit environments.

Footnotes

  • Supported in part by the Kansas Lions Sight Foundation, Inc (MAM), grant EY-12951 from the National Eye Institute, Bethesda MD (JRS), and a grant from Alcon (JRS).

  • The authors have no proprietary interests in the development or marketing of any product mentioned in this study.

Responses to this article

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.